Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Product Overview

Dapagliflozin Tablets belong to the antidiabetic therapeutic class and are a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Unlike many antidiabetic agents that act on pancreatic insulin secretion, it reduces renal glucose reabsorption and increases urinary glucose excretion independent of insulin. It achieves effective glycemic control while offering additional cardiorenal protective benefits.

Indications

This formulation is indicated for the treatment of type 2 diabetes mellitus in adult patients to improve glycemic control. It is also used for heart failure and chronic kidney disease management.

Specifications & Packaging

Specifications: 5 mg, 10 mg 

Packaging: 30 tablets / bottle

Quality & Supply Advantage

Manufactured in full GMP compliance, the tablets conform to international quality standards, with stringent control over impurities, dissolution and stability. We guarantee stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

Product Highlights

As a well-established SGLT2 inhibitor, it features an insulin-independent glucose-lowering mechanism and once-daily oral administration. Widely adopted in endocrinology, cardiology and nephrology practice, it meets global clinical demands for type 2 diabetes, heart failure and chronic kidney disease management.

Collaboration Options

We are able to supply qualified finished dosage forms, offer technology transfer and other flexible cooperation models. We welcome your enquiries for further information and potential collaboration.